The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While https://allenbvdz502792.ka-blogs.com/92267222/glp-3-retatrutide-a-comparative-analysis